Genetic Analysis AS Logo

Genetic Analysis AS

Develops microbiome diagnostics to detect gut dysbiosis for clinical and pharma partners.

GEAN | SPGR

Overview

Corporate Details

ISIN(s):
NO0010692130 (+2 more)
LEI:
5493004G3I23R6STCD61
Country:
Norway
Address:
Ulvenveien 80B, 0581 Oslo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genetic Analysis AS is a research-driven diagnostics company specializing in the human microbiome market. The company develops and commercializes diagnostic solutions based on its proprietary GA-map® platform, a standardized technology for characterizing the microbiome. Its flagship product is the GA-map® Dysbiosis Test Lx, a CE-marked in-vitro diagnostic test used to identify and characterize gut bacterial imbalances (dysbiosis) in patients with conditions such as IBS and IBD. Genetic Analysis serves laboratory diagnostics, clinical research, and pharmaceutical clients, offering tools for routine testing and the co-development of companion diagnostics to support targeted drug therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Genetic Analysis AS filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genetic Analysis AS

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Genetic Analysis AS via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Entero Therapeutics, Inc. Logo
Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.
United States of America ENTO
Entrada Therapeutics, Inc. Logo
Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.
United States of America TRDA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea 183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden ENZY
Developing alopecia therapies, skin regeneration products, and preclinical CRO services.
South Korea 446440
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden EQL
Equillium, Inc. Logo
Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.
United States of America EQ
Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America ERAS
Ernexa Therapeutics Inc. Logo
Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.
United States of America ERNA
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France ERYP

Talk to a Data Expert

Have a question? We'll get back to you promptly.